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Abstract
Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an oncoembryonic antigen. Because of its expression on
the cell surface of leukemia cells from patients with chronic lymphocytic leukemia (CLL), but not on normal B-cells or
other postpartum tissues, ROR1 is an attractive candidate for targeted therapies. UC-961 is a ﬁrst-in-class humanized
monoclonal antibody that binds the extracellular domain of ROR1. In this article we outline some of the preclinical
studies leading to an investigational new drug designation, enabling clinical studies in patients with CLL.
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Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is a
type I surface protein expressed during embryogenesis, where it
contributes polarized migration and organogenesis.1-3 It contains
a transmembrane domain, a cytoplasmic tyrosine kinase-like
domain, and extracellular ligand binding domains, including a
cysteine-rich domain homologous to Frizzled receptors for various
Wnt factors.2 The expression of ROR1 is developmentally regu-
lated. Expression of ROR1 attenuates during fetal development and
becomes negligible at term. Normal postpartum tissues lack surface
expression of the ROR1 protein, with the exception of
hematogones.4
Gene expression studies identiﬁed distinctive expression of
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http://dx.doi.org/10.1016/j.clml.2015.02.010normal B lymphocytes.5,6 Analysis of autoantibodies produced
by patients immunized with autologous leukemia cells transduced
to express CD154 identiﬁed that these autoantibodies recognized
ROR1 protein on the leukemia cell surface.7 Functional studies
found that ROR1 could serve as a receptor for Wnt5a, which
induces noncanonical Wnt signaling, leading to enhanced leukemia
cell survival; also anti-ROR1 antibodies produced by some patents
could neutralize the prosurvival effects of Wnt5a on leukemia cells
in vitro.7 Downstream signaling from ROR1 apparently activates
the phosphoinositide 3-kinase/protein kinase B (AKT)/mammalian
target of rapamycin pathway,8,9 and studies in other cancer cell lines
suggest that ROR1 might be a pseudokinase that serves as a sub-
strate for other signaling molecules, such as Met proto-oncogene
(MET), also known as hepatocyte growth factor receptor.10,11
Receptor Tyrosine Kinase-Like
Orphan Receptor 1-Targeted
Therapies and Derivation of UC-961
Because of its tumor speciﬁc expression and potential functional
signiﬁcance, ROR1 has been of interest as a target for novel
immunotherapies. An early report of anti-ROR1 monoclonal
antibodies (mAbs) screened using phage display for optimal
binding found that these mAbs typically bound the N-terminal region
of the extracellular immunoglobulin-like domain of ROR1, but had
limited direct cytotoxicity for human CLL cells.12 One of these mAbs
(designated 2A2) is currently under exploration as a part of antibody
drug conjugates or chimeric antigen receptor-expressing T-cells.13-16Clinical Lymphoma, Myeloma & Leukemia June 2015 - S167
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Preclinical Speciﬁcity and Safety of CirmtuzumabHowever, other groups have produced naked mAbs capable of
directly inducing apoptosis of CLL cells.17 We screened hybridomas
for production of mAbs mimicking the activity of anti-ROR1 au-
toantibodies that we observed in some patients vaccinated against
autologous leukemia cells.7 We also examined the activity of various
mAbs in vivo using a ROR1 transgenic mouse model of CLL.8 We
identiﬁed one mAb, D10, of relatively low afﬁnity that could inhibit
activation of AKT and engraftment of ROR1-positive (ROR1þ)
leukemia cells in this model. Mapping the epitope bound by this
mAb allowed us to generate mAbs of substantially higher afﬁnity for
ROR1 that retained this distinctive biologic activity. We humanized
the variable regions of one such mAb (designated UC-961, or
cirmtuzumab), which maintained high binding afﬁnity (Dissocia-
tion constant ¼ 2 nM) for the functional epitope of ROR1.
Preclinical Speciﬁc and Safety
Studies of UC-961
Studies with other anti-ROR1 mAbs have found potential
expression of ROR1 on adipose tissue and pancreatic islet cells.15Figure 1 (A) Pancreatic Cancer Control; and (B) Negative Staining of
Cross-React With Normal Adult Human Tissues. UC-961 Wa
Donors, Supplemented With a Positive Control Specimen (P
Good Laboratory Practice Regulations. (A) The UC-961 Stai
Receptor Tyrosine Kinase-Like Orphan Receptor 1-Positive P
the High Concentration on Any of the Normal Human Tissu
- Clinical Lymphoma, Myeloma & Leukemia June 2015Therefore, we performed a Good Laboratory Practice-compliant
human tissue cross-reactivity study with UC-961 before proceeding
with clinical testing of this mAb. Samples from all human tissues
from 3 separate donors were probed with UC-961 at the concen-
trations up to 5 times the optimal staining concentration for
ROR1þ cancer tissue.18 We did not observe any cross-reactivity
with normal postpartum tissues, including the pancreas or adipose
tissue (Figure 1).
We conducted rodent and primate studies to assess for
off-target or noneROR1-speciﬁc activity. Groups of Sprague-
Dawley rats (15 of each sex) received UC-961 at doses of
40 to 400 mg/kg using intravenous (I.V.) administration weekly
for 5 doses over 28 days. Clinical signs, body weight, clinical
pathology, and safety pharmacology measurements were
assessed during the study. Twenty animals (10 of each sex)
in each dosing cohort were sacriﬁced 3 days after the ﬁnal
UC-961 injection, and the remaining animals were sacriﬁced
on day 56. In all groups, UC-961 was well tolerated and no
adverse effects were noted. At terminal sacriﬁce, gross pathologicNormal Postpartum Tissues and Control Tissues. UC-961 Does Not
s Applied to Full Tissue Lists of Human Tissues From 3 Separate
ancreatic Carcinoma). This Was Conducted in Compliance With
ning Resulted in Strong (Grade 3) Positive Staining Intensity on
ancreatic Tumor Cells. (B) There Was No Tissue Cross-Reactivity at
es. Representative Photomicrographs Are Shown
Michael Y. Choi et alexaminations were normal and no untoward pathology was
observed.
We also performed studies in cynomolgus monkeys. UC-961 was
administered once using I.V. injection at a dosage of 40 mg/kg.
There were no changes in body weight, clinical chemistry values, or
hematologic parameters, including absolute numbers of T or B cells.
Pharmacokinetic evaluation of plasma samples indicated the elimi-
nation half-life of UC-961 was > 14 days.
Discussion
Monoclonal antibodies are effective agents in the therapy of
patients with CLL or other cancers. Treatment of patients with
mAbs has provided prolonged survival alone or in combination with
chemotherapy.19,20 To date, mAbs currently used in the treatment
of patients with CLL are mostly directed against CD20, an antigen
also found on normal B cells. As such, treatment with such mAbs
can cause depletion of normal B cells and potentially enhance
posttreatment hypogammaglobulinemia. Agents directed against
CD19, CD37, CD52, or other antigens also are being evaluated.21
However, none of these antigens are unique to CLL cells, poten-
tially limiting their therapeutic index by targeting noncancer cells,
resulting in immune suppression or other risks. Targeting ROR1
might be advantageous because it is a tumor-speciﬁc antigen that
has functional importance to CLL cells.
UC-961 targets a distinctive epitope of ROR1 and has biologic
activity against ROR1þ tumor cells. Preclinical studies did not
detect toxicity. This might be because UC-961 does not have
detectable binding activity for normal postpartum tissues. However,
human trials will be necessary to determine the safety and activity of
this mAb in the therapy for patients with CLL. To this end, a phase
I trial is currently enrolling (NCT02222688). This also will provide
another opportunity to evaluate the functional effect of targeting
ROR1 on CLL in vivo.
The implications of this work extend beyond CLL. ROR1 is
broadly expressed in many types of cancer and not their normal
tissue counterparts.18 Although the prevalence of ROR1 expression
in solid tumors does not appear to be as high as it is in CLL, its
expression is found in cancers that are poorly differentiated and that
have high relapse rates and high metastatic potential.9,22,23 More
recent studies have identiﬁed ROR1 on the cancer stem cells in
ovarian cancer.24 Moreover, treatment of immune-deﬁcient mice
engrafted with ovarian cancer patient-derived xenografts (PDX)
with UC-961 could induce senescence in the cancer stem cells,
thereby inhibiting the growth of the ovarian cancer PDX and its
capacity to re-engraft other immune-deﬁcient mice.24 As such,
UC-961 might have broader applications in the treatment of
patients with solid-tumor malignancies in addition to the treatment
of patients with CLL.
Clinical Practice Points
 ROR1 is an oncoembryonic protein that is expressed by a variety
of human cancers, including CLL, but not by normal adult
tissue.
 UC-961 (Cirmtuzumab) is a ﬁrst-in-class ROR1-targeted
monoclonal antibody that binds to and has functional activity
against cancer cells, but NOT against normal adult tissues. We did not observe UC-961 to have any off-target activity or
toxicity in preclinical tests.
 We currently are conducted a Phase 1 study of UC-961 in pa-
tients with relapsed or refractory CLL.
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